A Phase 2 interventional study of Fluticasone propionate in Asthma, sponsored by GlaxoSmithKline. Completed at 2 sites in New Zealand. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2016-09-15.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Inhaling AMP causes an inflammatory response in the lung. This study will investigate whether 5-days of treatment with fluticasone propionate protects the lung from responding to the AMP in this way.
A randomised, double-blind, placebo-controlled, incomplete block, 4-period crossover study to investigate the effects of 5-day repeat inhaled doses of fluticasone propionate (BID, 50-2000 mcg) on airway responsiveness to adenosine-5'-monophosphate (AMP) challenge when delivered after the last dose in mild asthmatic subjects
3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.
This study's enrollment of 49 is below the median of 83 across 2,752 interventional studies indexed under Asthma.
Browse Asthma studies →GlaxoSmithKline is the lead sponsor of 3,562 studies on the registry; 117 are open to participants now.
Of its 258 completed or terminated interventional studies of FDA-regulated products, 232 (90%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
study drug
Drug: Fluticasone propionate
Study drug
To characterise the dose response curve following repeat inhaled doses of FP for 5 days in the AMP challenge model.
Time frame: 5 days
Safety following multiple AMP challenges: Adverse events
Time frame: 5 days
Plasma concentrations of FP and derived pharmacokinetic parameters
Time frame: 5 days
Exhaled nitric oxide concentrations
Time frame: 5 days
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GlaxoSmithKline